var data={"title":"Albuterol (salbutamol): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Albuterol (salbutamol): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5577?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">see &quot;Albuterol (salbutamol): Drug information&quot;</a> and <a href=\"topic.htm?path=albuterol-salbutamol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Albuterol (salbutamol): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130976\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ProAir HFA;</li>\n      <li>ProAir RespiClick;</li>\n      <li>Proventil HFA;</li>\n      <li>Ventolin HFA;</li>\n      <li>VoSpire ER [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130977\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Airomir;</li>\n      <li>Ventolin Diskus;</li>\n      <li>Ventolin HFA;</li>\n      <li>Ventolin I.V. Infusion;</li>\n      <li>Ventolin Nebules P.F.;</li>\n      <li>Ventolin Respirator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056301\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Beta<sub>2</sub>-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431419\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchodilation:</b> Limited data available: Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Nebulization:</i> Usual reported dose: 1.25 to 2.5 mg/dose (Ballard 2002). In a retrospective report, 16 VLBW neonates (mean GA: 26.1 &plusmn; 1.2 weeks; mean birthweight: 817 &plusmn; 211 g) received 1.25 mg/dose every 8 hours for &gt;2 weeks (Mhanna 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Inhalation, aerosol (metered dose inhaler); mechanically ventilated patients:</i> 90 mcg/spray: 1 to 2 puffs administered into the ventilator circuit was the most frequently reported dose in a survey of 68 neonatal intensive care units (Ballard 2002); typically used every 6 hours (Fok 1998); may consider more frequent use if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hyperkalemia; adjunct therapy:</b> Limited data available: Oral inhalation: Nebulization: 0.4 mg (in 2 mL of NS) every 2 hours was administered to premature neonates (GA: 25 &plusmn; 1 weeks; PNA: 5 &plusmn; 1 days)  with a birthweight &lt;2 kg (736 &plusmn; 89 g) and serum potassium concentration &ge;6 mEq/L in a randomized, placebo controlled, double blind study (treatment group: n=8); administration continued until serum potassium levels were &lt;5 mEq/L or maximum of 12 doses were administered; results showed potassium serum concentrations significantly declined   in the first 4 hours of albuterol treatment compared to placebo and continued to be lower at 8 hours after first dose; mean number doses administered was 6 doses (Singh 2002).  <b>Note:</b> Albuterol should be not be used as the sole agent for treating severe hyperkalemia, especially in patients with renal failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056294\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">see &quot;Albuterol (salbutamol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Asthma, acute exacerbation:</b> Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Outpatient:<i> Inhalation aerosol (metered dose inhaler):</i> 90 mcg/puff: Children and Adolescents: 2 to 6 puffs every 20 minutes (GINA 2014; NAEPP 2007); if good response after 2 doses then every 3 to 4 hours for 24 to 48 hours (NAEPP 2007); <b>Note:</b> GINA guideline dosing is based on the 100 mcg/puff salbutamol product (not available in U.S.) (GINA 2014) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Emergency care/hospital: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Inhalation aerosol (metered dose inhaler):</i> 90 mcg/puff:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children: Limited data available in ages &lt;4 years: 4 to 8 puffs every 20 minutes for 3 doses then every 1 to 4 hours (NAEPP 2007 )</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: 4 to 8 puffs every 20 minutes for up to 4 hours then every 1 to 4 hours (NAEPP 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Nebulization: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children: Limited data in ages &lt;2 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Intermittent: 0.15 mg/kg (minimum dose: 2.5 mg) every 20 minutes for 3 doses then 0.15 to 0.3 mg/kg not to exceed 10 mg every 1 to 4 hours (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Continuous: Dosing regimens variable; optimal dosage not established:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">NIH Guidelines: 0.5 mg/kg/hour (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Alternate dosing: Limited data available: 0.3 mg/kg/hour has also been used safely in the treatment of severe status asthmaticus in children (Papo 1993); higher doses of 3 mg/kg/hour &plusmn; 2.2 mg/kg/hour in children (n=19, mean age: 20.7 months &plusmn; 38 months) resulted in no cardiotoxicity (Katz 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Intermittent: 2.5 to 5 mg every 20 minutes for 3 doses then 2.5 to 10 mg every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Continuous: 10 to 15 mg/hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Asthma, maintenance therapy (nonacute)</b> (NAEPP 2007): Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Inhalation, aerosol (metered dose inhaler):</i> Infants, Children, and Adolescents: Limited data available in ages &lt;4 years: 90 mcg/puff: 2 puffs every 4 to 6 hours as needed. <b>Note:</b> Not recommended for long-term daily maintenance treatment; regular use exceeding 2 days/week for symptom control (not prevention of exercise-induced bronchospasm) indicates the need for additional long-term control therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Nebulization:</i> Limited data in ages &lt;2 years: </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Albuterol Nebulization Dosage</caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">0.5% Solution</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">0.083% Solution</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Frequency</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Infants and Children &lt;5 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.63 to 2.5 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.13 to 0.5 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.76 to 3 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 4 to 6 h</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Children &ge;5 y and Adolescents</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.25 to 5 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25 to 1 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5 to 6 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 4 to 8 h</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchospasm, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Inhalation, aerosol (metered dose inhaler):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Manufacturer's labeling: Children &ge;4 years and Adolescents: 90 mcg/puff: 1 to 2 puffs every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing: Limited data available: Infants, Children, and Adolescents: 90 mcg/puff: 4 to 8 puffs every 15 to 20 minutes for 3 doses; then every 1 to 4 hours (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Nebulization:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\"> Manufacturer labeling: Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">10 to 15 kg: 1.25 mg 3 to 4 times/day </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;15 kg: 2.5 mg 3 to 4 times/day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing: Limited data available (Hegenbarth 2008): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Intermittent: 0.5% (5 mg/mL) solution: 2.5 mg every 20 minutes for 3 doses, then 0.15 to 0.3 mg/kg up to 10 mg every 1 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Continuous (prolonged nebulization): 0.5 mg/kg/hour up to 10 to 15 mg/hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: <b>Note:</b> Not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (GINA 2014; GINA 2014a; NAEPP 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Immediate release formulation (syrup, tablets):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 2 to 6 years: 0.1 to 0.2 mg/kg/dose 3 times daily; maximum dose: 4 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 6 to 12 years: 2 mg/dose 3 to 4 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\"> Adolescents: 2 to 4 mg/dose 3 to 4 times daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Sustained release formulation (tablets): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &ge;6 years: 0.3 to 0.6 mg/kg/<b>day</b> divided twice daily; maximum daily dose: 8 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: 4 mg/dose twice daily; may increase to 8 mg/dose twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exercise-induced bronchospasm; prevention:</b> (NAEPP 2007; Parsons 2013): Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Inhalation, aerosol (metered dose inhaler):</i> Limited data available in ages &lt;4 years: 90 mcg/puff: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children &lt;5 years: 1 to 2 puffs 5 to 20 minutes before exercising </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;5 years and Adolescents: 2 puffs 5 to 20 minutes before exercising </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia; adjunct therapy:</b> Limited data available: Infants, Children, and Adolescents : Oral inhalation: <i>Nebulization:</i> 10 mg/dose or 0.3 to 0.5 mg/kg/dose has been used by some centers and based on experience that has shown the effective nebulization for hyperkalemia is 4 times more than the bronchodilatory dose (Furhman 2011; Weiner 1998; Weisburg 2008). <b>Note:</b> Albuterol should be not be used as the sole agent for treating severe hyperkalemia, especially in patients with renal failure. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchospasm: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Metered dose inhaler (90 mcg/puff):</i> 2 puffs every 4 to 6 hours as needed (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Acute treatment: 1 to 2 puffs; additional puffs may be necessary if inadequate relief; however, patients should be advised to promptly consult health care provider or seek medical attention if no relief from acute treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: 1 to 2 puffs 3 to 4 times daily (maximum: 8 puffs daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Nebulization:</i> 2.5 mg 3 to 4 times daily as needed; Quick relief: 1.25 to 5 mg every 4 to 8 hours as needed (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Oral:</i> <b>Note:</b> Oral is not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Regular release: 2 to 4 mg/dose 3 to 4 times daily; maximum dose not to exceed 32 mg daily (divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release: 8 mg every 12 hours; maximum dose not to exceed 32 mg/day (divided doses). A 4 mg dose every 12 hours may be sufficient in some patients, such as adults of low body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exacerbation of asthma (acute, severe)</b> (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metered dose inhaler: 4 to 8 puffs every 20 minutes for up to 4 hours, then every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization solution: 2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to 10 mg every 1 to 4 hours as needed, or 10 to 15 mg/hour by continuous nebulization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exercise-induced bronchospasm (prevention):</b> <i>Metered dose inhaler (90 mcg/puff):</i> 2 puffs 5 to 30 minutes prior to exercise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: Use with caution in patients with renal impairment. No dosage adjustment required, including patients on hemodialysis, peritoneal dialysis, or CRRT (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130951\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProAir RespiClick: 90 mcg/actuation (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProAir HFA: 90 mcg/actuation (8.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proventil HFA: 90 mcg/actuation (6.7 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ventolin HFA: 90 mcg/actuation (8 g, 18 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.63 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VoSpire ER: 4 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VoSpire ER: 8 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130935\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20995164\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">see &quot;Albuterol (salbutamol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">ProAir HFA 8.5 g canisters, ProAir RespiClick 0.65 g inhaler, Proventil HFA 6.7 g canisters, and Ventolin HFA 18 g canisters contain 200 inhalations. Ventolin HFA 8 g canisters contain 60 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056305\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral inhalation: In infants and children &lt;4 years, a face mask with either the metered dose inhaler or nebulizer is recommended (GINA 2014a; NAEPP 2007)  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inhalation, aerosol (metered dose inhaler): Prime the inhaler (before first use or if it has not been used for more than 2 weeks) by releasing 4 test sprays into the air away from the face (3 test sprays for ProAir HFA); shake well before use; use spacer for children &lt;5 years of age and consider adding a face mask for infants and children &lt;4 years of age. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebulization: Concentrated solutions (&ge; 0.5%) should be diluted prior to use; adjust nebulizer flow to deliver dosage over 5 to 15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. For continuous nebulization, the total amount of fluid delivered is determined by nebulizer delivery device; usually 25 to 30 mL per 1 hour of nebulization, protocols may vary by institution (Hegenbarth 2008). Blow-by administration is not recommended; use a mask device if patient is unable to hold mouthpiece in mouth for administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food; do not crush or chew extended release tablets </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130969\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered-dose inhalers (HFA aerosols): Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Do not store at temperature &gt;120&deg;F. Do not puncture. Do not use or store near heat or open flame.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ventolin HFA: Discard when counter reads 000 or 12 months after removal from protective pouch, whichever comes first. Store with mouthpiece down.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dry powder inhalers:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProAir RespiClick: Store between 15&deg;C and 25&deg;C (59&deg;F and 77&deg;F). Avoid exposure to extreme heat, cold, or humidity. Discard 13 months after opening the foil pouch, or when the counter displays 0, whichever comes first</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ventolin Diskus [Canadian product]: Store at &le;30&deg;C (86&deg;F). Keep in a dry place. Protect from frost and light. Diskus is nonrefillable and should be discarded after all doses have been administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion solution [Canadian product]: Ventolin IV: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. After dilution, discard unused portion after 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization solution: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Do not use if solution changes color or becomes cloudy. Products packaged in foil should be used within 1 week (or according to the manufacturer's recommendations) if removed from foil pouch.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, extended release: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056304\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of bronchospasm in patients with reversible obstructive airway disease (Syrup: FDA approved in ages &ge;2 years and adults; Immediate release and extended release tablets: FDA approved in ages &ge;6 years and adults). <b>Note:</b> Although an FDA approved indication, the use of oral albuterol for management of acute asthma or long-term daily maintenance treatment is not recommended due to long onset of action and risk of side effects (GINA 2008; GINA 2012; NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation aerosol (metered dose inhaler): Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease; prevention of exercise-induced \tbronchospasm (All indications: FDA approved in ages &ge;4 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization solution: Treatment of bronchospasm in patients with reversible obstructive airway disease (FDA approved in ages &ge;2 years and adults; Proventil: FDA \tapproved in ages &ge;12 years and adults); treatment of acute attacks of bronchospasm (FDA approved in ages &ge;2 years and adults; Proventil: FDA approved in ages &ge;12 years and adults). <b>Note:</b> Approval ages for generics may vary; consult prescribing information for details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131035\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuterol may be confused with Albutein, atenolol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proventil may be confused with Bentyl, PriLOSEC, Prinivil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Salbutamol may be confused with salmeterol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ventolin may be confused with phentolamine, Benylin, Vantin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131033\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of adverse effects is dependent upon age of patient, dose, and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Chest discomfort, chest pain, edema, extrasystoles, flushing, hypertension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, ataxia, depression, dizziness, drowsiness, emotional lability, excitement (children and adolescents 2 to 14 years), fatigue, headache, hyperactivity (children and adolescents 6 to 14 years), insomnia, malaise, migraine, nervousness, pain, restlessness, rigors, shakiness (children and adolescents 6 to 14 years), vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, pallor (children 2 to 6 years), skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Diabetes mellitus, increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia (children 2 to 6 years), diarrhea, dyspepsia, eructation, flatulence, gastroenteritis, gastrointestinal symptoms (children 2 to 6 years), glossitis, increased appetite (children and adolescents 6 to 14 years), nausea, unpleasant taste (inhalation site), viral gastroenteritis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Difficulty in micturition, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, decreased white blood cell count, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Cold symptoms, infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Application site reaction (HFA inhaler)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, hyperkinesia, leg cramps, muscle cramps, musculoskeletal pain, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Conjunctivitis (children 2 to 6 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otalgia, otitis media, ear disease, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, bronchospasm (exacerbation of underlying pulmonary disease), cough, dyspnea, epistaxis (children and adolescents 6 to 14 years), exacerbation of asthma, flu-like symptoms, increased bronchial secretions, laryngitis, nasal congestion, nasopharyngitis, oropharyngeal edema, oropharyngeal pain, pharyngitis, pulmonary disease, respiratory tract disease, rhinitis, sinus headache, sinusitis, throat irritation, upper respiratory tract infection, upper respiratory tract inflammation, viral upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Accidental injury, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, atrial fibrillation, exacerbation of diabetes mellitus, gag reflex, glossitis, hyperglycemia, hypokalemia, hypotension, ketoacidosis, lactic acidosis, paradoxical bronchospasm, peripheral vasodilation, supraventricular tachycardia, tongue ulcer </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130958\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation, Oral: Hypersensitivity to albuterol or any component of the formulation; severe hypersensitivity to milk proteins (dry powder inhalers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Ventolin: Hypersensitivity to albuterol or any component of the formulation; tachyarrhythmias; risk of abortion during first or second trimester</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation: Tocolytic use in patients at risk of premature labor or threatened abortion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130939\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents (may be fatal); this should be distinguished from inadequate response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Albuterol is a short-acting beta<sub>2</sub>-agonist (SABA) that should be used as needed for quick relief of asthma symptoms. Based on a step-wise treatment approach using asthma guidelines, monotherapy without concurrent use of a long-term controller medication should only be reserved for patients with mild, intermittent forms of asthma without the presence of risk factors (Step 1 and/or exercise-induced) (GINA 2016; NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, heart failure); beta-agonists may produce ECG changes (flattening of the T wave, prolongation of the QTc interval, ST segment depression) and/or cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta<sub>2</sub>-agonists may also increase risk of arrhythmias. In a scientific statement from the American Heart Association, albuterol has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate to major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose and aggravate preexisting diabetes and ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta<sub>2</sub>-agonists may decrease serum potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use spacer for children &lt;5 years of age and consider adding a face mask for infants and children &lt;4 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Powder for oral inhalation contains lactose; hypersensitivity reactions (eg, anaphylaxis, angioedema, pruritus, and rash) have been reported in patients with milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819726\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">CNS stimulation, hyperactivity, and insomnia occur more frequently in younger children than in adults. In children receiving oral albuterol therapy, erythema multiforme and Stevens-Johnson syndrome have been reported (rare). Outbreaks of lower respiratory tract colonization and infection have been attributed to contaminated multidose albuterol bottle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298694\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130944\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13290&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130947\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130961\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to albuterol has been established. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Albuterol is the preferred short acting beta-agonist when treatment for asthma is needed during pregnancy (ACOG 2008; GINA 2016; NAEPP 2007). If high doses are required during labor and delivery, monitoring of glucose concentrations in the newborn for 24 hours is recommended, especially in preterm infants (GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when needed to treat bronchospasm in pregnant women. Use of the injection (Canadian product; not available in the US.) is specifically contraindicated in women during the first or second trimester who may be at risk of threatened abortion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056300\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum potassium, oxygen saturation, heart rate, pulmonary function tests, respiratory rate, use of accessory muscles during respiration, suprasternal retractions; arterial or capillary blood gases (if patient's condition warrants)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130938\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Relaxes bronchial smooth muscle by action on beta<sub>2</sub>-receptors with little effect on heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130957\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization/oral inhalation: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CFC-propelled albuterol: 10 minutes (peak plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation powder: 30 minutes (peak plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HFA inhalers: 25 minutes (peak plasma concentration); ~56 minutes (peak FEV<sub>1</sub> effect)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Nebulization/oral inhalation: 2 to 6 hours; Oral: Immediate release: 4 to 6 hours; extended release tablets: Up to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to an inactive sulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Inhalation: 3.8 to ~5 hours; Oral: 3.7 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (30% as unchanged drug); feces (&lt;20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130960\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ProAir RespiClick Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (1): $67.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (ProAir HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (8.5 g): $71.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Proventil HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (6.7 g): $95.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Ventolin HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (8 g): $25.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Albuterol Sulfate Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.63 mg/3 mL (3 mL): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/3 mL (3 mL): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">(2.5 MG/3ML) 0.083% (3 mL): $1.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">(5 MG/ML) 0.5% (1): $0.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Albuterol Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/5 mL (473 mL): $43.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Albuterol Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $178.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $334.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Albuterol Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $587.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $587.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130963\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aero-Vent (PH);</li>\n      <li>Aerolin (BR, CN, GR, QA);</li>\n      <li>Aeromol (TH);</li>\n      <li>Airmax (CO);</li>\n      <li>Airomir (AU, BE, DK, ES, FI, FR, GB, LU, NO, SE, TW, UY);</li>\n      <li>Asmacaire (PH);</li>\n      <li>Asmadil (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Asmalat (LB);</li>\n      <li>Asmalin Pulmoneb (PH);</li>\n      <li>Asmanol (ZW);</li>\n      <li>Asmatol (AR);</li>\n      <li>Asmavent (ZW);</li>\n      <li>Asmed (ZW);</li>\n      <li>Asmidon (JP);</li>\n      <li>Asmol (SG);</li>\n      <li>Asmol CFC-Free (AU);</li>\n      <li>Assal (MX);</li>\n      <li>Asthalin (IN, LB, LK, NZ, RO, ZW);</li>\n      <li>Asthalin HFA (HK);</li>\n      <li>Asthalin Inhaler (TZ);</li>\n      <li>Asthavent (AE, ZA);</li>\n      <li>Asvimol (PH);</li>\n      <li>Avedox-FC (MX);</li>\n      <li>Azmacon (ID);</li>\n      <li>Bajapres (CO);</li>\n      <li>Bemin (EC);</li>\n      <li>Bresaltec (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Brodil (BD);</li>\n      <li>Brodil HFA (BD);</li>\n      <li>Broncho-Spray (DE);</li>\n      <li>Bronchosol (TH);</li>\n      <li>Broncolin (MY, PH);</li>\n      <li>Brondisal (ID);</li>\n      <li>Bropil (CL);</li>\n      <li>Brytolin (PH);</li>\n      <li>Butalin (ET, JO, LB, SA);</li>\n      <li>Butamol (AR, AU, PY);</li>\n      <li>Butavent (MY);</li>\n      <li>Buto-Air (ES, MT);</li>\n      <li>Buto-Asma (BG, HK, PK, TH);</li>\n      <li>Butotal (CN);</li>\n      <li>Buventol (AE, AT, CZ, EE, LV, NO, SG, TW);</li>\n      <li>Buventol Easyhaler (TH);</li>\n      <li>Ciplabutol (EC);</li>\n      <li>Cotran (TW);</li>\n      <li>Cybutol (ID, LK);</li>\n      <li>Derihaler (ET, LK);</li>\n      <li>Durasol CR (LK);</li>\n      <li>Easyhaler Salbutamol (GB, IE);</li>\n      <li>Ecosal (BG, HR);</li>\n      <li>Etinoline (CN);</li>\n      <li>Farcolin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Farmarest (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Grafalin (ID);</li>\n      <li>Hivent DS (PH);</li>\n      <li>Huma-Salmol (HU);</li>\n      <li>Inbumed (MX);</li>\n      <li>Lebasma (ET);</li>\n      <li>Libretin (PH);</li>\n      <li>Medolin (SG);</li>\n      <li>Mozal (TW);</li>\n      <li>Nebsal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Respigen (NZ);</li>\n      <li>Sabutal (TW);</li>\n      <li>Salamol (CH, IE, MY);</li>\n      <li>Salapin (MT, NZ);</li>\n      <li>Salbetol (IN);</li>\n      <li>Salbo 2 (LK);</li>\n      <li>Salbron (ID);</li>\n      <li>Salbuflo (LK, PH);</li>\n      <li>Salbul (IE);</li>\n      <li>Salbulin (LU);</li>\n      <li>Salbutalan (MX);</li>\n      <li>Salbutamol (HU);</li>\n      <li>Salbutamol-GW (HU);</li>\n      <li>Salbutan (VE);</li>\n      <li>Salbutin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salbutol (KR);</li>\n      <li>Salbutrim (IL);</li>\n      <li>Salbuven (ID);</li>\n      <li>Salbuvent (PE);</li>\n      <li>Salmaplon (IN);</li>\n      <li>Salmolin (BD);</li>\n      <li>Salomol (TW);</li>\n      <li>Saltam (ID);</li>\n      <li>Salvent (ZW);</li>\n      <li>Solia (TH);</li>\n      <li>Sultanol (AT, DE, JP);</li>\n      <li>Synvent HFA (HK);</li>\n      <li>Teoden (BR);</li>\n      <li>Unibron (MX);</li>\n      <li>Velutine (ID);</li>\n      <li>Venalax (PH);</li>\n      <li>Venderol (SG);</li>\n      <li>Venetlin (JP);</li>\n      <li>Ventamol (ID);</li>\n      <li>Venterol (TH);</li>\n      <li>Venteze (ZA, ZW);</li>\n      <li>Ventilan (CO, PT);</li>\n      <li>Ventilastin (LT, RO);</li>\n      <li>Ventilastin Novolizer (DE, FR);</li>\n      <li>Ventodisk (LU);</li>\n      <li>Ventol (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ventolin (AE, AR, AU, BE, BF, BG, BH, BJ, BS, BZ, CH, CI, CL, CU, CY, CZ, DO, EE, EG, ES, ET, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, YE, ZM, ZW);</li>\n      <li>Ventolin CFC-Free (AU);</li>\n      <li>Ventolin HFA (BB, BM);</li>\n      <li>Ventoline (DK, FI, FR, NO, SE);</li>\n      <li>Ventylor (UA);</li>\n      <li>Volmax (AE, BH, CY, EC, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zenmolin (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zibil (MX);</li>\n      <li>Zomm (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. <i>Obstet Gynecol</i>. 2008;111(2 Pt 1):457-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.5% [prescribing information]. Orlando, FL: Nepron Pharmaceuticals Corporation; February 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.083% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.021% and 0.042% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ballard J, Lugo RA, and Salyer JW, &quot;A Survey of Albuterol Administration Practices in Intubated Patients in the Neonatal Intensive Care Unit,&quot; <i>Respir Care</i>, 2002, 47(1):31-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/11749685/pubmed\" target=\"_blank\" id=\"11749685\">11749685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boulton DW, Fawcett JP, and Fiddes TM, &quot;Transplacental Distribution of Salbutamol Enantiomers at Caesarian Section,&quot; <i>Br J Clin Pharmacol</i>,1997, 44(6):587-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9431837/pubmed\" target=\"_blank\" id=\"9431837\">9431837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fok TF, Lam K, Ng PC, et al, &quot;Randomised Crossover Trial of Salbutamol Aerosol Delivered by Metered Dose Inhaler, Jet Nebuliser, and Ultrasonic Nebuliser in Chronic Lung Disease,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 79(2):F100-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9828734/pubmed\" target=\"_blank\" id=\"9828734\">9828734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention in children 5 years and younger. 2014. Available at http://www.ginasthma.org/documents/3. Date accessed: January 12, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2014a. Available at www.ginaasthma.org Date accessed: January 12, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz RW, Kelly HW, Crowley MR, et al, &ldquo;Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children,&rdquo; <i>Pediatrics</i>, 1993, 92(5):666-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8414852/pubmed\" target=\"_blank\" id=\"8414852\">8414852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mhanna MJ, Patel JS, Patel S, et al, &quot;The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants,&quot; <i>Pediatr Pulmonol</i>, 2009, 44(8):778-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/19598281/pubmed\" target=\"_blank\" id=\"19598281\">19598281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program, &quot;Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002,&rdquo; <i>J Allergy Clin Immunol</i>, 2002, 110(5 Suppl):S141-219.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Callaghan C, Milner AD, and Swarbrick A, &ldquo;Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,&rdquo; <i>Arch Dis Child</i>, 1988, 63(5):479-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/3389861/pubmed\" target=\"_blank\" id=\"3389861\">3389861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papo MC, Frank J, and Thompson AE, &ldquo;A Prospective, Randomized Study of Continuous Versus Intermittent Nebulized Albuterol for Severe Status Asthmaticus in Children,&rdquo; <i>Crit Care Med</i>, 1993, 21(10):1479-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/8403956/pubmed\" target=\"_blank\" id=\"8403956\">8403956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society Clinical Practice Guideline: exercise-induced bronchoconstriction.<i> Am J Respir Crit Care Med</i>. 2013;187(9): 1016-1027.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/23634861/pubmed\" target=\"_blank\" id=\"23634861\">23634861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo; <i>J Allergy Clin Immunol</i>, 1985, 76(3):409-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2863296/pubmed\" target=\"_blank\" id=\"2863296\">2863296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Parkin P, Rajan A, et al, &ldquo;High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,&rdquo; <i>Pediatrics</i>, 1989, 83(4):513-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2927990 /pubmed\" target=\"_blank\" id=\"2927990 \">2927990 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Reider MJ, Canny G, et al, &ldquo;Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,&rdquo; <i>Pediatrics</i>, 1990, 86(4):509-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/2216613/pubmed\" target=\"_blank\" id=\"2216613\">2216613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates. <i>J Pediatr</i>. 2002;141(1):16-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/12091845 /pubmed\" target=\"_blank\" id=\"12091845 \">12091845 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. <i>J Am Soc Nephrol</i>. 1998;9(8):1535-1543.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/9697678 /pubmed\" target=\"_blank\" id=\"9697678 \">9697678 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisberg LS. Management of severe hyperkalemia. <i>Crit Care Med</i>. 2008;36(12):3246-3251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information/abstract-text/18936701 /pubmed\" target=\"_blank\" id=\"18936701 \">18936701 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13290 Version 207.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130976\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130977\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056301\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431419\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056294\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130951\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F130935\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F20995164\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056305\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F130969\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056304\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131035\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131033\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130958\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130939\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819726\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298694\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130944\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130947\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130961\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056300\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130938\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F130957\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130960\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130963\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13290|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=albuterol-salbutamol-drug-information\" class=\"drug drug_general\">Albuterol (salbutamol): Drug information</a></li><li><a href=\"topic.htm?path=albuterol-salbutamol-patient-drug-information\" class=\"drug drug_patient\">Albuterol (salbutamol): Patient drug information</a></li></ul></div></div>","javascript":null}